Tammy Sussman MD
@ta_sussman
Melanoma oncologist @DanaFarber . Tweets are my own.
ID: 1049459157299077120
09-10-2018 00:38:55
182 Tweet
233 Takipçi
156 Takip Edilen
New #JITC article: Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab ow.ly/NItm50GyIpC Allison Betof Warner, MD, PhD Jedd Wolchok Michael Postow
Stunning NEW research presented FIRST TIME in ASCO Plenary Series: ECOG-ACRIN Cancer Research Group phase III DREAMseq by Dr. Atkins Georgetown Lombardi=> Even for oncogene-driven melanoma: IO 1st rather than targeted therapy leads to better survival for most patients! Kimmie Ng, MD, MPH Melissa L. Johnson Robin Zon, MD, FACP, FASCO
JUST IN via ASCO alert: U.S. FDA approved pembrolizumab Merck for the adjuvant treatment of adult & pediatric (≥12 y) patients w/stage IIB/IIC melanoma post resection. Results based on KEYNOTE-716 presented Jason Luke, MD, FACP ESMO - Eur. Oncology #ESMO21 OncoAlert accessdata.fda.gov/drugsatfda_doc…
#ASHKudos Raj Chakraborty for 🤩😎 talk on QOL in long term #myeloma #BMT survivors from Fred Hutchinson Cancer Center #iNSPIRE/CIBMTR #SCP studies
So proud Dr. Jennifer McQuade Chris(tine) Spencer Jennifer Wargo MD Carrie Daniel Mac Melanoma team MD Anderson Cancer Center for paving way to harness power of microbiome & improve IO outcomes Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response science.org/doi/10.1126/sc…
Congratulations Immunocore and all patients dealing with #ocularmelanoma !!! #KIMMTRAK #tebetefusp approved by U.S. FDA FDA Oncology !! A major step forward for our patients. Blessed to have been part of this The Angeles Clinic ir.immunocore.com/news-releases/…
New data led by Tammy Sussman MD on impact of #TE on survival in pts with melanoma receiving chemo and/or IO #ASCO2022 #CleClinicCancer. Poster up now.
JUST IN: For the 22nd consecutive year, Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News Health! And photos from few min ago while coming to work ! Dana-Farber The Jimmy Fund Dana-Farber Lank Center for Genitourinary Oncology ms.spr.ly/6016jE6vE
#ESMO2022 Melanoma Session- Prof. Dirk Schaddendorf presenting OS benefit from adjuvant high dose ipi (3) + nivo (1) in resected/radiated Stage IV melanoma - IMMUNED study now published in The Lancet. Impressive outcome including some patients with Brain Mets post-SRS
Incredible achievement positive Phase 3 trial with TIL congrats John Haanen & colleagues @NKI. Game changer/new era to improve patient outcomes. FDA approval never too soon! Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma | NEJM nejm.org/doi/full/10.10…